Brooks Laboratories Ltd.

₹58.86

-2.9 (-4.7%)

BROOKS Share Price

Pharmaceuticals & Biotechnology

As on April 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 173 Cr

P/E Ratio-17.4

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	63.4	Bearish
10-DMA	64.52	Bearish
20-DMA	63.83	Bearish
50-DMA	63.21	Bearish
100-DMA	70.91	Bearish
200-DMA	102.79	Bearish

Historical Performance

1 Year

-56.1%

3 Years

-6.8%

5 Years

-26.6%

10 Years

-11.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	826	795	632	912	772
Total Expenditure	812	764	896	1,054	767
Other Income	45	11	2	8	7
Operating Profit	58	42	-262	-134	13
Interest	10	8	22	31	31
Depreciation	16	18	70	74	71
Profit Before Tax	-98	-196	-384	-239	-90
Consolidated Net Profit	-100	-196	-209	-113	-194
Adjusted EPS	-3	-7	-8	-5	-8

Compounded Sales Growth

10 Years:1.3

5 Years:1.3

3 Years:-2

TTM:0.8

Compounded Profit Growth

10 Years:-12.4

5 Years:-12.4

3 Years:-2.5

TTM:-12.6

Stock Price CAGR

10 Years:-1.2

5 Years:-6.9

3 Years:-2.3

TTM:-55.5

Return on Equity

10 Years:N/A

5 Years:-7.8

3 Years:-8.4

last year:-3.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	295	262	247	247	247
Total Reserves	686	393	493	628	544
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	27	18	26	114	193
Other Current Liabilities	24	19	27	88	179
Short Term Borrowings	59	50	57	110	136
Total Liabilities	1,237	904	1,096	1,946	1,621
Capital Work in Progress	---	---	---	151	7
Long Term Loans & Advances	22	27	28	80	35
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	22	26	21	106	77
Total Current Assets	339	310	276	612	474
Total Assets	1,237	904	1,096	1,946	1,621
Adjusted Book Value	33	25	30	35	32

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -17.4, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -2.3%, indicating poor shareholder returns.
The stock carries a high beta of 1.3, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹58 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹826 million, indicating a relatively small business scale.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 445571.5

No. of Shares: 7570 (Approx)

Performance:-55.4%

P/L: ₹-554428.5

NIFTY Performance: -0.6%

1 day Top Gainers